Skip to main content
Key Specialties
Anesthesiology Cardiology Dermatology Diabetology Endocrinology Gastroenterology and Hepatology General Medicine Geriatrics Hematology Infectious Diseases Internal Medicine Nephrology Neurology Obstetrics and Gynecology Oncology Ophthalmology Pediatrics Psychiatry Radiology Respiratory Medicine Rheumatology Surgery Urology
Congress Coverage
ASH 2024 Annual Meeting 2024 ESMO Congress 2024 ERS Congress 2024 EASD Congress 2024 ESC Congress 2024 EAN Congress 2024 ASCO Annual Meeting 2024 ACC Congress
Clinical Collections
Women’s Health Knowledge Hub Advances in Alzheimer’s
Video

Keynote series | Spotlight on managing health in obesity

Obesity is a major contributor to cardiorenal metabolic disease, but its impact extends throughout the body. Understand how obesity can affect other organ systems and impact treatment, and whether weight-loss measures improve outcomes.

Launching: Thursday 24th April 2025
 
ADVANCED SEARCH
Log in
Top
Targeted Oncology
Published in:

19-07-2024 | Prostate Cancer | Letter to the Editor

Comment on: “Hematological Toxicity of PARP Inhibitors in Metastatic Prostate Cancer Patients with Mutations of BRCA or HRR Genes: A Systematic Review and Safety Meta‑analysis”

Authors: Jun Ma, Wei Han

Published in: Targeted Oncology | Issue 5/2024

Login to get access

Excerpt

The Editor, …
Literature
1.
Maiorano BA, De Giorgi U, Verzoni E, et al. Hematological toxicity of PARP inhibitors in metastatic prostate cancer patients with mutations of BRCA or HRR genes: a systematic review and safety meta-analysis. Target Oncol. 2024;19(1):1–11.CrossRefPubMed
2.
3.
Gao Y, Luo H, Yang R, et al. Safety and efficacy of Cox-Maze procedure for atrial fibrillation during mitral valve surgery: a meta-analysis of randomized controlled trials. J Cardiothorac Surg. 2024;19(1):140.CrossRefPubMedPubMedCentral
4.
Karimzadeh A, Soeiro P, Feuerecker B, et al. Improved quality of life in metastatic castration-resistant prostate cancer patients receiving consecutive cycles of (177)Lu-PSMA I&T. J Nucl Med. 2023;64(11):1765–71.CrossRefPubMed
5.
Bermann M, Legarra A, Munera AA, et al. Confidence intervals for validation statistics with data truncation in genomic prediction. Genet Sel Evol. 2024;56(1):18.CrossRefPubMedPubMedCentral
Metadata
Title
Comment on: “Hematological Toxicity of PARP Inhibitors in Metastatic Prostate Cancer Patients with Mutations of BRCA or HRR Genes: A Systematic Review and Safety Meta‑analysis”
Authors
Jun Ma
Wei Han
Publication date
19-07-2024
Publisher
Springer International Publishing
Published in
Targeted Oncology / Issue 5/2024
Print ISSN: 1776-2596
Electronic ISSN: 1776-260X
DOI
https://doi.org/10.1007/s11523-024-01082-9

Other articles of this Issue 5/2024

An Evidence-Based Rationale for Dose De-escalation of Subcutaneous Atezolizumab

  • Open Access
  • Original Research

Malignant Peripheral Nerve Sheath Tumor, a Heterogeneous, Aggressive Cancer with Diverse Biomarkers and No Targeted Standard of Care: Review of the Literature and Ongoing Investigational Agents

Model-Informed Development of a Cost-Saving Dosing Regimen for Sacituzumab Govitecan

  • Open Access
  • Original Research

Correction to: Moving T‑Cell Therapies into the Standard of Care for Patients with Relapsed or Refractory Follicular Lymphoma: A Review

Safety and Preliminary Efficacy of Once-Weekly Split-Dose Selinexor in Soft Tissue Sarcoma: Results of the Phase Ib METSSAR Clinical Trial

Author’s Reply to Ma et al.: “Hematological Toxicity of PARP Inhibitors in Metastatic Prostate Cancer Patients with Mutations of BRCA or HRR Genes: A Systematic Review and Safety Meta-analysis”

Women’s health knowledge hub

Elevate your patient care with our comprehensive, evidence-based medical education on women's health. Designed to help you provide exceptional care for your female patients at every stage of life, we provide expert insights into topics such as reproductive health, menopause, breast cancer and sex-specific health risks and precision medicine.

Read more

Incorporating comprehensive genomic profiling into the standard-of-care for NSCLC and thyroid cancer

In this interactive webinar, experts Dr. Subbiah, Dr. Drilon, and Dr. Williams discuss best pathological practices within NSCLC and thyroid cancer, as well as how genomic testing can improve outcomes in clinical practice, using patient case studies as illustrations.

This content is intended only for US-based healthcare providers.

Supported by:
  • Illumina, Inc., and Eli Lilly and Company
Dr. Vivek Subbiah
Dr. Alexander Drilon
Dr. Michelle Williams
Developed by: Springer Healthcare
Watch now
Video

Elevate your expertise in aplastic anemia (Link opens in a new window)

Transform the way you care for your patients with aplastic anemia with our 3-module series using real-world case studies and expert insights. Discover why early diagnosis matters, explore the benefits and risks of current treatments, and develop tailored approaches for complex cases. 

Supported by:
  • Pfizer
Developed by: Springer Healthcare IME
Learn more
Image Credits